Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novolizer: how does it fit into inhalation therapy?

Helgo Magnussen1

  • 1Hospital Grosshansdorf, Center for Pneumology and Thoracic Surgery, Grosshansdorf, Germany. magnussen@pulmoresearch.de

Current Medical Research and Opinion
|September 6, 2005
PubMed
Summary

Incorrect inhaler use is common, especially with pressurized metered dose inhalers (pMDIs). The Novolizer dry powder inhaler (DPI) offers advantages like breath-activation and user-friendly design, potentially improving medication delivery and patient compliance for asthma and COPD management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The total-breath method yields higher values of DLCO and TLC than the conventional method.

BMC pulmonary medicine·2024
Same author

A new approach for the detection of obesity-related airway obstruction in lung-healthy individuals.

Respiratory medicine·2022
Same author

Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET.

Respiratory research·2021
Same author

The role of clinical signs and spirometry in the diagnosis of obstructive airway diseases: a systematic analysis adapted to general practice settings.

Journal of thoracic disease·2021
Same author

Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study.

Respiratory research·2021
Same author

Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline.

International journal of chronic obstructive pulmonary disease·2020

Area of Science:

  • Respiratory medicine
  • Pharmacology
  • Biomedical engineering

Background:

  • Inhalation therapy is crucial for delivering anti-asthmatic drugs directly to the lungs.
  • Many patients struggle with correct inhaler technique, particularly with pressurized metered dose inhalers (pMDIs), leading to under-treatment.
  • Dry powder inhalers (DPIs) offer advantages over pMDIs, including breath-activation and environmental benefits.

Purpose of the Study:

  • To evaluate the Novolizer, a breath-activated multidose DPI, as an alternative to pMDIs.
  • To assess key parameters for correct DPI use: usability, particle size distribution, and airflow resistance.
  • To compare the Novolizer's performance with another DPI, the Turbuhaler.

Main Methods:

  • Evaluation of the Novolizer's usability, feedback mechanisms, and dose counter.

Related Experiment Videos

  • Assessment of particle size distribution, specifically the fine particle fraction (FPF).
  • Measurement of intrinsic airflow resistance and comparison of peak inspiratory flow (PIF) rates with Turbuhaler.

    • Main Results:

    • The Novolizer is user-friendly with features guiding correct inhalation technique and monitoring compliance.
    • It demonstrates comparable or superior lung deposition to Turbuhaler at similar or higher PIF rates.
    • The Novolizer achieves a clinically effective FPF, relatively independent of flow rate, with better metering reproducibility than Turbuhaler.

    Conclusions:

    • The Novolizer's low-to-medium airflow resistance facilitates correct use across diverse patient groups, including children and those with severe asthma or COPD.
    • Its advanced DPI technology, including breath-activation and effective drug delivery, may enhance patient compliance.
    • The Novolizer presents a promising option for improving inhalation therapy outcomes.